Scholarlink

Background <p>Vaginal cancer is a rare gynecological malignant disease. In Japan, the proportion of vaginal cancer cases is estimated to increase as the population ages. The purpose of this study is to evaluate the age-specific incidence, treatment options, and prognosis of vaginal cancer in Japan.</p> Methods <p>This retrospective observational study used the Japan Society of Obstetrics and Gynecology tumor registry database. Patient characteristics included age, year diagnosed with vaginal cancer (2016–2020), and cancer stages, histological types, and treatment methods. The 2016 and 2017 dataset included follow-up time, survival status, and cause of death.</p> Results <p>A total of 746 patients were diagnosed with vaginal cancer from 2016 to 2020. The median age of the patients was 72&#xa0;years. Radiotherapy was most chosen as the primary treatment option for all ages and stages. Surgery was selected mostly in stage I and II (<i>n</i> = 118, 22.2% of these stage patients). Five-year overall survival for stages I, II, III, and IV was 87.6%, 55.6%, 59.9%, and 15.3%, respectively. Multivariate analysis showed that 3&#xa0;year OS was significantly better for patients who underwent surgery than those who received chemotherapy (HR 3.11, <i>P</i> = 0.00389) and those who received radiation therapy (HR 2.89, <i>P</i> = 0.0241), but not compared with concurrent chemoradiotherapy (HR 1.21, <i>P</i> = 0.7091). Histological type did not significantly affect prognosis. For stages I and II, surgery resulted in a better prognosis than radiation (<i>P</i> = 0.03).</p> Conclusions <p>Radiation therapy is the primary treatment for vaginal cancer; however, surgery may be an effective option in early-stage vaginal cancer when cases are appropriately selected.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival and prognostic factors in vaginal cancer: an analysis of 2016–2020 nationwide data

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Tatsuhiko Shigeto,
  • Yoshihito Yokoyama,
  • Wataru Yamagami,
  • Fumiaki Takahashi,
  • Hideki Tokunaga,
  • Eiko Yamamoto,
  • Kiyoshi Yoshino,
  • Kei Kawana,
  • Satoru Nagase

摘要

Background

Vaginal cancer is a rare gynecological malignant disease. In Japan, the proportion of vaginal cancer cases is estimated to increase as the population ages. The purpose of this study is to evaluate the age-specific incidence, treatment options, and prognosis of vaginal cancer in Japan.

Methods

This retrospective observational study used the Japan Society of Obstetrics and Gynecology tumor registry database. Patient characteristics included age, year diagnosed with vaginal cancer (2016–2020), and cancer stages, histological types, and treatment methods. The 2016 and 2017 dataset included follow-up time, survival status, and cause of death.

Results

A total of 746 patients were diagnosed with vaginal cancer from 2016 to 2020. The median age of the patients was 72 years. Radiotherapy was most chosen as the primary treatment option for all ages and stages. Surgery was selected mostly in stage I and II (n = 118, 22.2% of these stage patients). Five-year overall survival for stages I, II, III, and IV was 87.6%, 55.6%, 59.9%, and 15.3%, respectively. Multivariate analysis showed that 3 year OS was significantly better for patients who underwent surgery than those who received chemotherapy (HR 3.11, P = 0.00389) and those who received radiation therapy (HR 2.89, P = 0.0241), but not compared with concurrent chemoradiotherapy (HR 1.21, P = 0.7091). Histological type did not significantly affect prognosis. For stages I and II, surgery resulted in a better prognosis than radiation (P = 0.03).

Conclusions

Radiation therapy is the primary treatment for vaginal cancer; however, surgery may be an effective option in early-stage vaginal cancer when cases are appropriately selected.